C. Deng

发表

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Stephen Green, B. Caleb, G. Schwartz, 2008, Molecular Cancer Therapeutics.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

J. Breed, V. Oza, P. Lyne, 2012, Journal of medicinal chemistry.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

V. Oza, P. Lyne, J. Janetka, 2008, Bioorganic & medicinal chemistry letters.

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.

J. Breed, P. Lyne, J. Janetka, 2018, Journal of Medicinal Chemistry.

Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

J. Wendoloski, P. Lyne, S. Ashwell, 2004, Journal of medicinal chemistry.

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

Jon Read, Mei Su, J. Breed, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

B. Caleb, G. Schwartz, J. Janetka, 2008, Molecular Cancer Therapeutics.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

P. Lyne, J. Janetka, S. Ashwell, 2008, Bioorganic & medicinal chemistry letters.